Results 121 to 130 of about 133,754 (301)
This study delineates a novel HSP90AB1‐ITGBL1 signaling axis governing osteosarcoma. HSP90AB1 promotes K63‐linked ubiquitination and proteasomal degradation of ITGBL1. Restoring ITGBL1 induces reactive oxygen species‐dependent endoplasmic reticulum stress and pro‐death autophagy, suppressing tumor growth and metastasis.
Zhen Wang +17 more
wiley +1 more source
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. [PDF]
BackgroundIncreasing studies implicate cancer stem cells (CSCs) as the source of resistance and relapse following conventional cytotoxic therapies. Few studies have examined the response of CSCs to targeted therapies, such as tyrosine kinase inhibitors ...
Ames, Erik +11 more
core +2 more sources
ABSTRACT Our previous clinical trials had demonstrated that neoadjuvant hypofractionated radiotherapy (HFRT) combined with immunotherapy yields promising clinical outcomes in locally advanced rectal cancer (LARC). However, this combined modality benefits only a subset of patients, highlighting the need to uncover the mechanisms underlying how ...
Lichao Liu +12 more
wiley +1 more source
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou +9 more
wiley +1 more source
High‐grade serous ovarian carcinoma (HGSOC) is plagued by platinum resistance, with malignant ascites closely linked to poor outcomes. Here, we identify ASCOR, a circRNA enriched in ascites small extracellular vesicles (sEVs) from platinum‐resistant HGSOC patients, as a predictor of poor survival. ASCOR enhances platinum resistance in vitro and in vivo
Hanyuan Liu +10 more
wiley +1 more source
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. [PDF]
Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast ...
Chien, A Jo +5 more
core
NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2− Breast Cancer
Multi‐omics and single‐cell analyses identify activated NK cells as key mediators of anti‐PD‐(L)1 response in HR+/HER2− breast cancer. Platinum chemotherapy enhances NK cell cytotoxicity through NF‐κB–associated signaling, synergizing with immunotherapy and providing a rationale for combination treatment.
Yi‐Yu Chen +8 more
wiley +1 more source
The study identifies a NIPAL1‐driven metabolic‐epigenetic circuit in esophageal squamous cell carcinoma that promotes glycolysis, lactate accumulation, and H3K18 histone lactylation, forming a self‐sustaining loop that suppresses CD8+ T cell immunity.
Ri‐Xin Chen +15 more
wiley +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source

